Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140885 | 1.00 | CDK1 (0.47) | CDK1CDK2CDK4CCNB1CCNT1 | |
| Trifluoroacetic Acid SCHEMBL2149345 | 0.92 | CDK1 (0.45) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL30860873 | 0.84 | LRRK2 (0.38) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL27228246 | 0.84 | LRRK2 (0.38) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL2148905 | 0.82 | LRRK2 (0.37) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL2522284 | 0.82 | LRRK2 (0.37) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL2149347 | 0.79 | CCNT1 (0.35) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL26664440 | 0.79 | TRPM8 (0.37) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL31081933 | 0.79 | TRPM8 (0.37) | CDK1CDK2CDK4CCNB1CCNT1 | |
| SCHEMBL13648310 | 0.77 | CDK1 (0.49) | CDK1CDK2CCNB1LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342185-B1 | SULFON SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | CDK6, CDK4, CDK9 | CDK1 6/4885CDK2 4/4885CDK4 2/4885 |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | CDK1 160/4885CDK2 49/4885CDK4 373/4885 |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | CDK1 6/4885CDK2 4/4885CDK4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.